154 related articles for article (PubMed ID: 36808754)
1. Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.
Le Gall-Ianotto C; Ficheux AS; Lippert E; Herbreteau L; Rio L; Pan-Petesch B; Misery L; Ianotto JC
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1175-1183. PubMed ID: 36808754
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.
Le Gall-Ianotto C; Verdet R; Nowak E; Le Roux L; Gasse A; Fiedler A; Carlhant-Kowalski D; Marcorelles P; Misery L; Ianotto JC
Trials; 2021 Dec; 22(1):938. PubMed ID: 34923994
[TBL] [Abstract][Full Text] [Related]
3. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
[TBL] [Abstract][Full Text] [Related]
4. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
[TBL] [Abstract][Full Text] [Related]
5. Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis.
Le Gall-Ianotto C; Le Calloch R; Couturier MA; Chauveau A; Lippert E; Carré JL; Misery L; Ianotto JC
J Thromb Haemost; 2019 Nov; 17(11):1950-1955. PubMed ID: 31344312
[TBL] [Abstract][Full Text] [Related]
6. Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics.
Lelonek E; Matusiak Ł; Wróbel T; Szepietowski JC
Acta Derm Venereol; 2018 Apr; 98(5):496-500. PubMed ID: 29437189
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
8. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
[No Abstract] [Full Text] [Related]
9. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
10. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic Burden, and Thrombosis.
Ümit E; Baysal M; Kırkızlar HO; Demir AM
Turk J Haematol; 2024 May; ():. PubMed ID: 38801033
[TBL] [Abstract][Full Text] [Related]
12. Burden of Aquagenic Pruritus in Polycythaemia Vera.
Lelonek E; Matusiak Ł; Wróbel T; Kwiatkowski J; Szepietowski JC
Acta Derm Venereol; 2018 Feb; 98(2):185-190. PubMed ID: 28971208
[TBL] [Abstract][Full Text] [Related]
13. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
16. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
17. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm].
Tan YX; Xu N; Huang JX; Wu WE; Liu L; Zhou LL; Liu XL; Yin CX; Xu D; Zhou X
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):576-582. PubMed ID: 32810965
[No Abstract] [Full Text] [Related]
19. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
20. [The relationship between symptom burden and hematologic responses after treatment with interferon/hydroxyurea in patients with polycythemia vera].
Liu D; Xu ZF; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):635-641. PubMed ID: 34547868
[No Abstract] [Full Text] [Related]
[Next] [New Search]
